{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T06:27:43Z","timestamp":1782628063508,"version":"3.54.5"},"reference-count":52,"publisher":"SAGE Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2022,12,6]]},"abstract":"<jats:p>Background: Abnormal intracellular expression and aggregation of \u03b1-synuclein (\u03b1-syn) is the histopathological hallmark of several neurodegenerative diseases especially Parkinson\u2019s disease. However, safe and efficient approaches to clear \u03b1-syn remain unavailable. Objective: This study aimed to investigate the process of peripheral catabolism of brain-derived \u03b1-syn. Methods: Thirty patients with atrioventricular reentrant tachycardia (AVRT) (left accessory pathways) who underwent radiofrequency catheter ablation (RFCA) were enrolled in this study. Blood was collected via catheters from superior vena cava (SVC), inferior vena cava (IVC) proximal to the hepatic vein (HV), the right femoral vein (FV), and femoral artery (FA) simultaneously during RFCA. Plasma \u03b1-syn levels of AVRT patients and soluble \u03b1-syn levels of the brain samples were measured using enzyme-linked immunosorbent assay kits. Results: The \u03b1-syn concentrations in different locations of veins were divided by time-matched arterial \u03b1-syn concentrations to generate the venous\/arterial (V\/A) ratio. The V\/A ratio of \u03b1-syn from the SVC was 1.204 (1.069\u20131.339, 95% CI), while the V\/A ratio of \u03b1-syn from IVC was 0.831 (0.734\u20130.928, 95% CI), suggesting that brain-derived \u03b1-syn in the arterial blood was physiologically cleared while going through the peripheral organs and tissues. And it was estimated that about half of brain soluble \u03b1-syn could efflux and be cleared in the periphery. Moreover, the glomerular filtration rate was found correlated with V-A difference (FA-ICV) (p\u200a=\u200a0.0272). Conclusion: Under physiological conditions, brain-derived \u03b1-syn could efflux into and be catabolized by the peripheral system. The kidney may play a potential role in the clearance of \u03b1-syn.<\/jats:p>","DOI":"10.3233\/jad-220742","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T11:45:48Z","timestamp":1666093548000},"page":"1485-1492","source":"Crossref","is-referenced-by-count":3,"title":["A Conceptual Study on the Peripheral Clearance of Brain-Derived \u03b1-Synuclein in Humans"],"prefix":"10.1177","volume":"90","author":[{"given":"Chi","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China"},{"name":"Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China"},{"name":"Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China, Chengdu, China"},{"name":"Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Le","family":"Bu","sequence":"additional","affiliation":[{"name":"Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China"},{"name":"Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China"},{"name":"Institute of Brain and Intelligence, Third Military Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang-Sheng","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China"},{"name":"Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China"},{"name":"Institute of Brain and Intelligence, Third Military Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Jiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China"},{"name":"Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China"},{"name":"Institute of Brain and Intelligence, Third Military Medical University, Chongqing, China"},{"name":"State Key Laboratory of Trauma, Burns and Combined Injury, Third Military Medical University, Chongqing, China"},{"name":"Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-220742_ref1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/jnc.13570","article-title":"The contribution of alpha synuclein to neuronal survival and function \u2013 Implications for Parkinson\u2019s disease","volume":"137","author":"Benskey","year":"2016","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-220742_ref2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.3233\/JAD-220742_ref3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrneurol.2012.242","article-title":"100 years of Lewy pathology","volume":"9","author":"Goedert","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-220742_ref4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/nan.12312","article-title":"Review: Noveltreatment strategies targeting alpha-synuclein in multiple systematrophy as a model of synucleinopathy","volume":"42","author":"Valera","year":"2016","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.3233\/JAD-220742_ref5","doi-asserted-by":"crossref","first-page":"E5308","DOI":"10.1073\/pnas.1514475112","article-title":"Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism","volume":"112","author":"Prusiner","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-220742_ref6","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1006\/nbdi.2000.0286","article-title":"Accumulation of insoluble alpha-synuclein in dementia with Lewy bodies","volume":"7","author":"Campbell","year":"2000","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JAD-220742_ref7","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1126\/science.274.5290.1197","article-title":"Mapping of a gene for Parkinson\u2019s disease to chromosome 4q21-q23","volume":"274","author":"Polymeropoulos","year":"1996","journal-title":"Science"},{"key":"10.3233\/JAD-220742_ref8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ana.10795","article-title":"The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia","volume":"55","author":"Zarranz","year":"2004","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-220742_ref9","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"alpha-Synuclein locus triplication causes Parkinson\u2019s disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"key":"10.3233\/JAD-220742_ref10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ng0298-106","article-title":"Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson\u2019s disease","volume":"18","author":"Kruger","year":"1998","journal-title":"Nat Genet"},{"key":"10.3233\/JAD-220742_ref11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/nan.12298","article-title":"Review: Sporadic Parkinson\u2019s disease: Development and distribution of alpha-synuclein pathology","volume":"42","author":"Del Tredici","year":"2016","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.3233\/JAD-220742_ref12","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1038\/emboj.2009.257","article-title":"Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson\u2019s disease models","volume":"28","author":"Karpinar","year":"2009","journal-title":"EMBO J"},{"key":"10.3233\/JAD-220742_ref13","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1073\/pnas.1100976108","article-title":"In vivo demonstration that alpha-synuclein oligomers are toxic","volume":"108","author":"Winner","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-220742_ref14","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cell.2012.03.037","article-title":"Direct observation of the interconversion of normal and toxic forms of alpha-synuclein","volume":"149","author":"Cremades","year":"2012","journal-title":"Cell"},{"key":"10.3233\/JAD-220742_ref15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-94-007-5416-4_6","article-title":"alpha-Synuclein aggregation and modulating factors","volume":"65","author":"Paleologou","year":"2012","journal-title":"Subcell Biochem"},{"key":"10.3233\/JAD-220742_ref16","doi-asserted-by":"crossref","first-page":"19555","DOI":"10.1073\/pnas.1318268110","article-title":"Transmission of multiple system atrophy prions to transgenic mice","volume":"110","author":"Watts","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 1","key":"10.3233\/JAD-220742_ref17","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/jnc.13517","article-title":"Parkinson\u2019s disease: Acid-glucocerebrosidase activity and alpha-synuclein clearance","volume":"139","author":"Blanz","year":"2016","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-220742_ref18","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","article-title":"Targeting alpha-synuclein for treatment of Parkinson\u2019s disease: Mechanistic and therapeutic considerations","volume":"14","author":"Dehay","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-220742_ref19","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3390\/biom10030391","article-title":"Targeting alpha-synuclein for PD therapeutics: A pursuit on all fronts","volume":"10","author":"Teil","year":"2020","journal-title":"Biomolecules"},{"key":"10.3233\/JAD-220742_ref20","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.expneurol.2005.12.024","article-title":"Silencing of human alpha-synuclein and in vitro and in rat brain using lentiviral-mediated RNAi","volume":"198","author":"Sapru","year":"2006","journal-title":"Exp Neurol"},{"key":"10.3233\/JAD-220742_ref21","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1172\/JCI64502","article-title":"shRNA targeting alpha-synuclein prevents neurodegeneration in a Parkinson\u2019s disease model","volume":"125","author":"Zharikov","year":"2015","journal-title":"J Clin Invest"},{"key":"10.3233\/JAD-220742_ref22","doi-asserted-by":"crossref","first-page":"8756","DOI":"10.1074\/jbc.M115.704973","article-title":"Complex effects of the ZSCAN21 transcription factor on transcriptional regulation of alpha-synuclein in primary neuronal cultures and in vivo","volume":"291","author":"Dermentzaki","year":"2016","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-220742_ref23","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1126\/science.aaf3934","article-title":"beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson\u2019s disease","volume":"357","author":"Mittal","year":"2017","journal-title":"Science"},{"key":"10.3233\/JAD-220742_ref24","doi-asserted-by":"crossref","first-page":"29739","DOI":"10.1074\/jbc.M600933200","article-title":"Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease","volume":"281","author":"Anderson","year":"2006","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-220742_ref25","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1073\/pnas.0406976102","article-title":"Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson\u2019s disease-linked mutations","volume":"102","author":"Li","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-220742_ref26","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1021\/acschembio.7b00113","article-title":"O-GlcNAcylation of alpha-synuclein at Serine 87 reduces aggregation without affecting membrane binding","volume":"12","author":"Lewis","year":"2017","journal-title":"ACS Chem Biol"},{"key":"10.3233\/JAD-220742_ref27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0002-9440(10)63633-4","article-title":"Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies","volume":"163","author":"Sampathu","year":"2003","journal-title":"Am J Pathol"},{"key":"10.3233\/JAD-220742_ref28","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/brain\/awx056","article-title":"Glycation potentiates alpha-synuclein-associated neurodegeneration in synucleinopathies","volume":"140","author":"Vicente Miranda","year":"2017","journal-title":"Brain"},{"key":"10.3233\/JAD-220742_ref29","doi-asserted-by":"crossref","first-page":"e19338","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PLoS One"},{"key":"10.3233\/JAD-220742_ref30","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","article-title":"Next-generation active immunization approach for synucleinopathies: Implications for Parkinson\u2019s disease clinical trials","volume":"127","author":"Mandler","year":"2014","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-220742_ref31","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.celrep.2014.05.033","article-title":"Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and neurodegeneration","volume":"7","author":"Tran","year":"2014","journal-title":"Cell Rep"},{"key":"10.3233\/JAD-220742_ref32","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00401-015-1477-1","article-title":"Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer\u2019s disease","volume":"130","author":"Xiang","year":"2015","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-220742_ref33","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/ana.24270","article-title":"Amyloid-beta efflux from the central nervous system into the plasma","volume":"76","author":"Roberts","year":"2014","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-220742_ref34","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00401-018-1891-2","article-title":"Physiological clearance of tau in the periphery and its therapeutic potential for tauopathies","volume":"136","author":"Wang","year":"2018","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-220742_ref35","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1126\/science.1101738","article-title":"Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy","volume":"305","author":"Cuervo","year":"2004","journal-title":"Science"},{"key":"10.3233\/JAD-220742_ref36","doi-asserted-by":"crossref","first-page":"e1811","DOI":"10.1038\/cddis.2015.169","article-title":"Alpha-synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons","volume":"6","author":"Koch","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.3233\/JAD-220742_ref37","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1039\/C6MT00026F","article-title":"Alpha-synucle: Relating metals to structure, function and inhibition","volume":"8","author":"McDowall","year":"2016","journal-title":"Metallomics"},{"key":"10.3233\/JAD-220742_ref38","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.mcn.2015.12.012","article-title":"Alpha synuclein dimers and oligomers are increased in overexpressing conditions in vitro and in vivo","volume":"71","author":"Marmolino","year":"2016","journal-title":"Mol Cell Neurosci"},{"key":"10.3233\/JAD-220742_ref39","first-page":"1158","article-title":"Transmission of soluble and insoluble alpha-synuclein to mice","volume":"74","author":"Jones","year":"2015","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-220742_ref40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fnins.2015.00059","article-title":"Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson\u2019s disease","volume":"9","author":"Gallegos","year":"2015","journal-title":"Front Neurosci"},{"key":"10.3233\/JAD-220742_ref41","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12640-015-9576-2","article-title":"Pathogenesis and therapeutic strategies in Alzheimer\u2019s disease: From brain to periphery","volume":"29","author":"Yu","year":"2016","journal-title":"Neurotox Res"},{"key":"10.3233\/JAD-220742_ref42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.peptides.2014.09.018","article-title":"Alpha synuclein is transported into and out of the brain by the blood-brain barrier","volume":"62","author":"Sui","year":"2014","journal-title":"Peptides"},{"key":"10.3233\/JAD-220742_ref43","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ana.24648","article-title":"Pathological alpha-synuclein in gastrointestinal tissues from prodromal Parkinson\u2019s disease patients","volume":"79","author":"Stokholm","year":"2016","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-220742_ref44","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S1474-4422(16)00080-6","article-title":"Assessment of alpha-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: A case-control study","volume":"15","author":"Vilas","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-220742_ref45","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3233\/JAD-201038","article-title":"alpha-synuclein heteromers in red blood cells of Alzheimer\u2019s disease and Lewy body dementia patients","volume":"80","author":"Daniele","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-220742_ref46","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.nbd.2017.04.004","article-title":"Alpha-synucle: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson\u2019s disease","volume":"109","author":"Rocha","year":"2018","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JAD-220742_ref47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nm.4269","article-title":"alpha-synuclein toxicity in neurodegeneration: Mechanism and therapeutic strategies","volume":"23","author":"Wong","year":"2017","journal-title":"Nat Med"},{"key":"10.3233\/JAD-220742_ref48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-1326-3-19","article-title":"In vivo silencing of alpha-synuclein using naked siRNA","volume":"3","author":"Lewis","year":"2008","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JAD-220742_ref49","doi-asserted-by":"crossref","first-page":"E1817","DOI":"10.1073\/pnas.1305623110","article-title":"TFEB-mediated autophagy rescues midbrain dopamine neurons from alpha-synuclein toxicity","volume":"110","author":"Decressac","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-220742_ref50","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/mds.26377","article-title":"Active immunization therapies for Parkinson\u2019s disease and multiple system atrophy","volume":"31","author":"Schneeberger","year":"2016","journal-title":"Mov Disord"},{"key":"10.3233\/JAD-220742_ref51","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/mds.26481","article-title":"Development of passive immunotherapies for synucleinopathies","volume":"31","author":"Bergstrom","year":"2016","journal-title":"Mov Disord"},{"key":"10.3233\/JAD-220742_ref52","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00401-015-1504-2","article-title":"Age-dependent defects of alpha-synuclein oligomer uptake in microglia and monocytes","volume":"131","author":"Bliederhaeuser","year":"2016","journal-title":"Acta Neuropathol"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-220742","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:07:54Z","timestamp":1777370874000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-220742"}},"subtitle":[],"editor":[{"given":"Jin-Tai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":52,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/jad-220742","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,6]]}}}